School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Room 609A, Lo Kwee-Seong Integrated Biomedical Sciences Building, Shatin, Hong Kong Special Administrative Region, People's Republic of China.
Diabetologia. 2013 Mar;56(3):553-62. doi: 10.1007/s00125-012-2801-0. Epub 2012 Dec 19.
AIMS/HYPOTHESIS: Vitamin D is necessary for normal insulin action and suppresses renin production. Increased renin-angiotensin system (RAS) activity causes islet damage, including reduced insulin secretion. We therefore sought to determine whether hypovitaminosis D-induced upregulation of islet RAS in vivo impairs islet cell function and increases insulin resistance, and whether pharmacological suppression of the RAS during continuing vitamin D deficiency might correct this.
C57BL/6 mice were rendered vitamin D-deficient by diet, and glucose and insulin tolerance was assessed. The expression and translation of islet functional, and islet RAS, genes were measured and the effects of pharmacological renin suppression examined.
Mice with diet-induced hypovitaminosis D developed impaired glucose tolerance, increased RAS component expression and impaired islet function gene transcription. Treatment with pharmacological renin inhibition (aliskiren), without vitamin D status correction, reduced islet RAS over-reactivity, islet dysfunction and insulin resistance, and improved glucose tolerance.
CONCLUSIONS/INTERPRETATION: Upregulation of islet RAS genes can contribute to hypovitaminosis D-induced impairment of islet function and increase insulin resistance independently of vitamin D status. Thus, our findings support the use of RAS inhibitors in impaired glucose homeostasis or early diabetes. They also suggest that combining RAS inhibition with correction of hypovitaminosis D might be useful in treating impaired glycaemic control and also in type 2 diabetes prevention. However, the use of aliskiren in established diabetes is contraindicated due to the increased risk of side effects such as hyperkalaemia, so other more suitable RAS blockers need to be identified.
目的/假设:维生素 D 是胰岛素正常作用所必需的,可抑制肾素的产生。血管紧张素系统(RAS)活性增加会导致胰岛损伤,包括胰岛素分泌减少。因此,我们试图确定体内维生素 D 缺乏诱导的胰岛 RAS 上调是否会损害胰岛细胞功能并增加胰岛素抵抗,以及在持续维生素 D 缺乏期间抑制 RAS 是否可以纠正这种情况。
通过饮食使 C57BL/6 小鼠出现维生素 D 缺乏,并评估葡萄糖和胰岛素耐量。测量胰岛功能和胰岛 RAS 基因的表达和翻译,并检查药理学抑制 RAS 的作用。
饮食诱导的维生素 D 缺乏症小鼠出现葡萄糖耐量受损、RAS 成分表达增加和胰岛功能基因转录受损。用药理学肾素抑制(阿利克仑)治疗,而不纠正维生素 D 状态,可降低胰岛 RAS 过度反应、胰岛功能障碍和胰岛素抵抗,并改善葡萄糖耐量。
结论/解释:胰岛 RAS 基因的上调可能导致维生素 D 缺乏症引起的胰岛功能障碍和胰岛素抵抗增加,而与维生素 D 状态无关。因此,我们的发现支持在葡萄糖稳态受损或早期糖尿病中使用 RAS 抑制剂。它们还表明,将 RAS 抑制与纠正维生素 D 缺乏症相结合,可能对治疗血糖控制受损以及预防 2 型糖尿病有用。然而,由于副作用(如高钾血症)的风险增加,阿利克仑在已确诊的糖尿病中的使用是禁忌的,因此需要确定其他更合适的 RAS 阻滞剂。